Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary A Piazza

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Cancers|June 12, 2026
Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading ResistanceSindhu Ramesh, Junwei Wang, Chung-Hui Huang, et al.
Journal of Ovarian Research|November 3, 2022
Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancerRebecca M Borneman, Elaine Gavin, Alla Musiyenko, et al.
Plos One|October 13, 2016
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule TherapeuticsW Joon Chung, Jennifer L Goeckeler-Fried, Viktoria Havasi, et al.
Oncotarget|October 21, 2017
Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signalingBing Zhu, Ashley Lindsey, Nan Li, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
The Journal of Urology|January 10, 2004
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statementIan M Thompson, Demetrius Albanes, Joseph W Basler, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer|March 14, 2025
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 29, 2021
Suppression of Colon Tumorigenesis in Mutant <i>Apc</i> Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-CateninKevin J Lee, Wen-Chi L Chang, Xi Chen, et al.
Pharmacological Reviews|March 13, 2025
Cyclic nucleotide phosphodiesterases as drug targetsMichy P Kelly, Viacheslav O Nikolaev, Leila Gobejishvili, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Cancers|June 12, 2026
Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading ResistanceSindhu Ramesh, Junwei Wang, Chung-Hui Huang, et al.
Journal of Ovarian Research|November 3, 2022
Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancerRebecca M Borneman, Elaine Gavin, Alla Musiyenko, et al.
Plos One|October 13, 2016
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule TherapeuticsW Joon Chung, Jennifer L Goeckeler-Fried, Viktoria Havasi, et al.
Oncotarget|October 21, 2017
Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signalingBing Zhu, Ashley Lindsey, Nan Li, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
The Journal of Urology|January 10, 2004
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statementIan M Thompson, Demetrius Albanes, Joseph W Basler, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer|March 14, 2025
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 29, 2021
Suppression of Colon Tumorigenesis in Mutant <i>Apc</i> Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-CateninKevin J Lee, Wen-Chi L Chang, Xi Chen, et al.
Pharmacological Reviews|March 13, 2025
Cyclic nucleotide phosphodiesterases as drug targetsMichy P Kelly, Viacheslav O Nikolaev, Leila Gobejishvili, et al.
Pageof 12